EGFR and non-small cell lung carcinoma: The clinical efficacies of epidermal growth factor receptor (EGFR) kinase inhibitors such as gefitinib and erlotinib are limited in EGFR-mutant non-small-cell lung cancer in which EGFR bears the gatekeeper substitution T790M25, 26.